Last reviewed · How we verify

NCT05745415

Cancer Stem Cell Specific Aptamer's Ability to Detect Blood Circulating Cancer Stem Cells and Its Role as a Predictor of Prognosis in Pancreatic Cancer

Completed Last updated 27 February 2023
What this trial tests

trial in Pancreatic Neoplasm in 40 participants. Completed in 29 March 2021.

Timeline
29 March 2018
Primary endpoint
29 March 2021
29 March 2021

Quick facts

Lead sponsorYonsei University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment40
Start date29 March 2018
Primary completion29 March 2021
Estimated completion29 March 2021
Sites1 location across South Korea

Conditions studied

Sponsor

Yonsei University

Who can join

20 and older, any sex, with Pancreatic Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The treatment performance of pancreatic cancer has not changed significantly over the past 20 years and is still less than 10%. In addition, 80-90% of pancreatic cancer patients are found to be already advanced at the time of diagnosis, and it is the best malignant tumor in the human body with a 5-year survival rate of less than 10% and a median survival period of less than 1 year. However, early diagnosis of pancreatic cancer is still difficult, and there is no effective treatment other than surgery, so the increase in long-term survival rate over the past 20 years has been insignificant or stagnant. The response rate to anticancer drug treatment after surgery or anticancer drug when surgery is not possible is only around 20%, so it is very urgent to discover new biomarkers in predicting drug resistance and recurrence after surgery and predicting prognosis in advance. Minimally non-invasive diagnostic techniques are very important to detect and track cancer progression in the clinic. In particular, histological diagnosis and analysis have limitations in carcinomas, such as pancreatic cancer, which are small and distant, making it difficult to obtain tissue samples. CA 19-9, a prognostic marker for existing pancreatic cancer, 1) has low specificity for early diagnosis of pancreas, 2) is not detected in lewis A, B antibody-negative patients, and 3) shows false positive in cases with cholangitis at the same time. Because it has many disadvantages, the development of prognostic biomarkers in blood is urgently needed. Recently, a study has been reported that the presence or absence of detection of circulating tumor cells is directly related to the prognosis of pancreatic cancer patients, and can be used for monitoring the patient's treatment response and for recurrence after surgery. In particular, the process of cancer metastasis consists of epithelial-to-mesenchymal transition and migration of cancer cells into the blood, and the existence of cancer stem cells is very important for metastasis and drug treatment resistance. Eventually, it is known to cause pancreatic cancer metastasis and recurrence. Cancer stem cells have the ability to self-renew, the capability of developing, multiple cell lineages, and the potential of extensive proliferation, and the ability to detect cancer stem cells in the blood is important in pancreatic cancer patients who are at high risk of metastasis and recurrence. It is a non-invasive screening tool. Comparatively evaluate the treatment response and prognosis of pancreatic cancer patients according to the characteristics and subtypes of circulating cancer cells.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Aptamers in neuro-oncology: An emerging therapeutic modality.
    Doherty C, Wilbanks B, Khatua S, Maher LJ. · · 2024 · cited 19× · PMID 37619244 · DOI 10.1093/neuonc/noad156
  2. Phenotypic characteristics of circulating tumor cells and predictive impact for efficacy of chemotherapy in patients with pancreatic cancer: a prospective study.
    Lee HS, Jung EH, Shin H, Park CS, et al · · 2023 · cited 4× · PMID 37736542 · DOI 10.3389/fonc.2023.1206565
  3. Designing the Future of Biosensing: Advances in Aptamer Discovery, Computational Modeling, and Diagnostic Applications.
    Jesky RG, Lo LHY, Siu RHP, Tanner JA. · · 2025 · PMID 41149291 · DOI 10.3390/bios15100637

Verify or expand the search:

Other recruiting trials for Pancreatic Neoplasm

Currently open trials in the same condition.

Other Yonsei University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05745415.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing